Egypt turns the page on shortages and creates a national stockpile to secure diabetes and medicines

Dr. Ali Al-Ghamrawi, President confirmed Egyptian Medicine AuthorityAll types of medicines have been provided for all therapeutic groups, the most important of which is diabetes treatment preparations and various products in the local market from last July until this, with a limit on which the Authority received any complaints about them.

The head of the Egyptian Medicines Authority said that about 9 and a half million preparation packages were pumped Treatment of diabetesMore than 2 million and 100 thousand packages of Mixtard Vial were pumped, about 350 thousand packages of Lantus, and more than 2 million and 600 thousand packages of Insulinagypt vial. More than 2 million and 300 thousand packages of other preparations representing different types of insulin were also pumped.

The Chairman of the Authority said that the amount of diabetes medicine containing metformin has increased to about 2 million 200,000 preparation packages containing metformin, and that the stock of raw material is sufficient for more than 6 million make a package of diabetes medicine.
The head of the Medicines Authority of Egypt continued that in terms of arrangements, about 2 million and 600 thousand packages of Urivin-N Eff have been released, and almost a million packages of Urosolvin, and that there are about 325 a thousand packages under production, and more. the 800 thousand packages of Epimag Eff There are about 316 thousand packages under production, and the stock of raw material is enough to make more than 11 million packages.

For his part, Dr. Yass Ragai, Deputy Chairman of the Egyptian Medicines Authority, confirmed that all preparations for the distribution of these therapeutic groups to all pharmacies in all government, and it was confirmed that they were available to all distributors across the country to ensure a continuous supply of these provisions.

The Deputy Chairman of the Authority said that the raw materials necessary for the preparation of diabetes treatment and preparations are provided in all local factories, and continuous manufacturing plans and processes are followed to ensure that any deficiencies in these therapeutic groups will be replicated. in total so that they are readily available in the markets and that normal levels of local circulation continue.

This comes within the framework of the Egyptian Pharmaceutical Authority’s efforts to provide pharmaceutical products from important therapeutic groups to ensure the health and safety of patients, and to meet their pharmaceutical needs.